As sales suffer on Incivek lag, Vertex hikes Kalydeco forecast; Family bickering stalls deal talk at Brazil's Aché;

@FiercePharma: Scary-odd news from Bloomberg: Amgen blood drugs may help victims survive nuclear attack. Story | Follow @FiercePharma

@EricPFierce: FDA tests the waters on Plan B, approves it for girls 15 and older, off the shelf but requires proof of age. Report | Follow @EricPFierce

> Vertex Pharmaceuticals' ($VRTX) revenue dropped 25% for the first quarter, thanks to faltering sales of its hepatitis C drug Incivek, but the company hiked forecasts for sales of its cystic fibrosis drug Kalydeco to $300 million to $340 million, $20 million more than previously. Release | Report

> A potential deal for Brazilian drugmaker Aché has run aground as family owners bicker over price, leaving rumored bidders Novartis ($NVS) and Abbott Laboratories ($ABT) hanging. Report (sub. req.)

> Roche's ($RHHBY) anti-inflammatory drug Actemra won a new indication in children with polyarticular juvenile idiopathic arthritis, a rare form of the disease. Report

> A federal judge tossed out a lawsuit alleging Amgen ($AMGN) hired corporate spies to steal trade secrets about Teva Pharmaceutical's ($TEVA) generic versions of blood drugs, saying Teva had "no factual basis" for its claim. Report (sub. req.)

> Denmark's Lundbeck posted a bigger-than-expected increase in quarterly earnings and affirmed its 2013 forecasts, aided by an expanded alliance with Japanese drugmaker Otsuka. Report

Medical Device News

@FierceMedDev: Natera hauls in $54.6M for prenatal Dx. News | Follow @FierceMedDev

@MarkHFierce: An MRI scan to measure brain atrophy could predict MS, a new University at Buffalo study has determined. More | Follow @MarkHFierce

 @DamianFierce: Join us for a trip through why a repeal of the medical device tax is unlikely to happen any time soon. Editor's Corner | Follow @DamianFierce

> Hospira pulling the plug on troubled devices. Report

> Fresenius Medical watches profits slip amid U.S. struggles. Article

> Cardiovascular Systems addresses U.S. government info request in insider trader investigation. Item

Biotech News

@FierceBiotech: ICYMI, check out newest Industry Voices: Time to Take Fecal Transplantation Seriously. Feature | Follow @FierceBiotech

@JohnCFierce: Seems likely to me that Merck is going to cut open R&D and do some major surgery. Perlmutter is two weeks on the job. | Follow @JohnCFierce

@RyanMFierce: Just talked to Semantelli about IMS Health deal: IMS Health acquires social media analytics startup Semantelli. Report | Follow @RyanMFierce

> Merck spotlights new deals, R&D review as demands to rebuild pipeline grow. Story

> VCs provide $40M to finance Celator's pivotal PhIII AML study. News

> FDA steamrolls over panel vote, spurns Titan's addiction drug Probuphine. Article

Biomarkers News

> Dozens of new biomarkers gauge ovarian cancer survival prospects. Report

> Investigators profile a lethal tumor cell that could spur metastasis. Article

> Verastem gears up for companion Dx mesothelioma treatment trial. More

> Brain atrophy could predict MS, study finds. Story

> Key biomarker measure + CT scan predict melanoma survival odds. Item

Drug Delivery News

@MichaelGFierce: Merck, Celgene cancer nanomeds combined for better delivery. Report | Follow @MichaelGFierce

> Researchers open window through blood-brain barrier. Story

> ClearPoint MRI-guided device sheds light on drug delivery to the brain. Editor's Corner

> 'Spider' protein can deliver stable vaccines in high concentration. More

> Insuline's InsuPatch delivery device suffers FDA setback. Item

And Finally... Disturbed by latest caffeinated chewing gum--not to mention caffeinated Cracker Jack--FDA eyes new limits. Report (sub. req.)

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.